Urate lowering therapy in primary care: rheum for improvement

Abstract

Primary care physicians (PCPs) play a critical role in the management of gout worldwide. However, significant gaps in gout care persist, underscoring the need for improved approaches to its management. While some guidelines, such as those from the American College of Physicians (ACP) published in 2016, support a more reactive treat-to-symptoms approach, others from the American College of Rheumatology (ACR) and the European Alliance Of Associations For Rheumatology advocate for a proactive treat-to-target (TTT) strategy-focused on achieving optimal serum urate levels through urate lowering therapy (ULT). This divergence reflects differing clinical priorities and differential interpretation of the evidence and it may contribute to variability in care delivery. Improving gout management requires greater engagement from both patients and healthcare providers, with particular emphasis on increasing adherence to ULT. Patients need enhanced support to better understand the importance of sustained urate lowering treatment, while healthcare providers may benefit from clearer guidance aligned with evidence-based strategies to foster greater patient trust and confidence. This article provides an overview of the current state of guidelines, highlights areas of agreement and discordance between them, and identifies key areas for improving care delivery. It additionally offers insight into alternative care delivery strategies, such as those involving non-physician health professionals, which have shown promise in enhancing patient outcomes. Future research should focus on continued development of innovative, multi-modal interventions to improve ULT adherence, including health system-based initiatives and collaborative care models.

Keywords

Gout / primary care / urate lowering therapy / treat-to-target / medication adherence

References

[1] Edwards NL, Schlesinger N, Clark S, Arndt T, Lipsky PE. Management of Gout in the United States: A Claims-based Analysis. ACR Open Rheumatol. 2020; 2: 180-7.

[2] Khormi AAM, Basalem AA, Al Muaddi AMZ, Alaskar AM, Algahtani RAS, Alharbi AS, et al. Knowledge and attitudes of gout patients and their perspectives about diagnosis and management: A cross-sectional study in Saudi Arabia. Immun Inflamm Dis. 2023; 11: e1010.

[3] Kwok TSH, Kuriya B, Hawker G, Li P, Choy G, Widdifield J. Serum Urate Monitoring Among Older Adults With Gout: Initiating Urate-Lowering Therapy in Ontario, Canada. Arthritis Care Res (Hoboken). 2023; 75: 2463-71.

[4] Kinge JM, Knudsen AK, Skirbekk V, Vollset SE. Musculoskeletal disorders in Norway: prevalence of chronicity and use of primary and specialist health care services. BMC Musculoskelet Disord. 2015; 16: 75.

[5] Roberts C, Adebajo AO, Long S. Improving the quality of care of musculoskeletal conditions in primary care. Rheumatology (Oxford). 2002; 41: 503-8.

[6] Oderda GM, Shiozawa A, Walsh M, Hess K, Brixner DI, Feehan M, et al. Physician adherence to ACR gout treatment guidelines: perception versus practice. Postgrad Med. 2014; 126: 257-67.

[7] Khanna P, Khanna D, Storgard C, Baumgartner S, Morlock R. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift. Postgrad Med. 2016; 128: 34-40.

[8] Mikuls TR, MacLean CH, Olivieri J, Patino F, Allison JJ, Farrar JT, et al. Quality of care indicators for gout management. Arthritis Rheum. 2004; 50: 937-43.

[9] FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020; 72: 744-60.

[10] Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017; 76: 29-42.

[11] Qaseem A, Harris RP, Forciea MA; Clinical Guidelines Committee of the American College of Physicians; Denberg TD, Barry MJ, Boyd C, Chow RD, Humphrey LL, Kansagara D, et al. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017; 166: 58-68.

[12] Aldahmashi H, Maneze D, Molloy L, Salamonson Y. Nurses’ adoption of diabetes clinical practice guidelines in primary care and the impacts on patient outcomes and safety: An integrative review. Int J Nurs Stud. 2024; 154: 104747.

[13] Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999; 318: 527-30.

[14] Dalbeth N, Bardin T, Doherty M, Lioté F, Richette P, Saag KG, et al. Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nat Rev Rheumatol. 2017; 13: 561-8.

[15] Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, et al.; British Society for Rheumatology Standards, Audit and Guidelines Working Group. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford). 2017; 56: e1-20.

[16] McLean RM. The Long and Winding Road to Clinical Guidelines on the Diagnosis and Management of Gout. Ann Intern Med. 2017; 166: 73-4.

[17] Duarte-García A, Zamore R, Wong JB. The Evidence Basis for the American College of Rheumatology Practice Guidelines. JAMA Intern Med. 2018; 178: 146-8.

[18] Ho GH, Pillinger MH, Toprover M. Adherence to gout guidelines: where do we stand? Curr Opin Rheumatol. 2021; 33: 128-34.

[19] FitzGerald JD, Neogi T, Choi HK. Editorial: Do Not Let Gout Apathy Lead to Gouty Arthropathy. Arthritis Rheumatol. 2017; 69: 479-82.

[20] Stamp LK, Dalbeth N. Moving urate-lowering therapy in gout beyond guideline recommendations. Semin Arthritis Rheum. 2024; 65: 152358.

[21] Solomon DH, Weissman JS, Choi H, Atlas SJ, Berardinelli C, Dedier J, et al. Designing a Strategy Trial for the Management of Gout: The Use of a Modified Delphi Panel. ACR Open Rheumatol. 2021; 3: 341-8.

[22] Yip RM, Cheung TT, So H, Chan JP, Ho CT, Tsang HH, et al.; Hong Kong Society of Rheumatology. The Hong Kong Society of Rheumatology consensus recommendations for the management of gout. Clin Rheumatol. 2023; 42: 2013-27.

[23] Pascart T, Latourte A, Flipo RM, Chalès G, Coblentz-Baumann L, Cohen-Solal A, et al. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy. Joint Bone Spine. 2020; 87: 395-404.

[24] Mikuls TR, Cheetham TC, Levy GD, Rashid N, Kerimian A, Low KJ, et al. Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial. Am J Med. 2019; 132: 354-61.

[25] Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet. 2018; 392: 1403-12.

[26] Dalbeth N, Billington K, Doyle A, Frampton C, Tan P, Aati O, et al. Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial. Arthritis Rheumatol. 2019; 71: 1739-46.

[27] Hao Y, Oon S, Nikpour M. Efficacy and safety of treat-to-target strategy studies in rheumatic diseases: A systematic review and meta-analysis. Semin Arthritis Rheum. 2024; 67: 152465.

[28] Stamp LK, Frampton C, Morillon MB, Taylor WJ, Dalbeth N, Singh JA, et al. Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials. Lancet Rheumatol. 2022; 4: e53-60.

[29] Cunha RN, Aguiar R, Farinha F. Impact of pegloticase on patient outcomes in refractory gout: current perspectives. Open Access Rheumatol. 2018; 10: 141-9.

[30] Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout (TRUST) [Internet]. [Cited 2024 Aug 15]. Available from: https://clinicaltrials.gov/study/NCT04875702

[31] Talaat M, Park K, Schlesinger N. Contentious Issues in Gout Management: The Story so Far. Open Access Rheumatol. 2021; 13: 111-22.

[32] Hill EM, Sky K, Sit M, Collamer A, Higgs J. Does starting allopurinol prolong acute treated gout? A randomized clinical trial. J Clin Rheumatol. 2015; 21: 120-5.

[33] Eminaga F, La-Crette J, Jones A, Abhishek A. Does the initiation of urate-lowering treatment during an acute gout attack prolong the current episode and precipitate recurrent attacks: a systematic literature review. Rheumatol Int. 2016; 36: 1747-52.

[34] Evidence reviews for timing of urate-lowering therapy in relation to a flare in people with gout: Gout: diagnosis and management: Evidence review F. London: National Institute for Health and Care Excellence (NICE); 2022.

[35] Tai V, Gow P, Stewart S, Satpanich P, Li C, Abhishek A, et al. An updated systematic review and meta-analysis of randomised controlled trials on the effects of urate-lowering therapy initiation during a gout flare. Semin Arthritis Rheum. 2024; 65: 152367.

[36] Juraschek SP, Kovell LC, Miller ER 3rd, Gelber AC. Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res (Hoboken). 2015; 67: 588-92.

[37] Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 2019; 71: 991-9.

[38] Doghramji PP, Fermer S, Wood R, Morlock R, Baumgartner S. Management of gout in the real world: current practice versus guideline recommendations. Postgrad Med. 2016; 128: 106-14.

[39] Owens D, Whelan B, McCarthy G. A survey of the management of gout in primary care. Ir Med J. 2008; 101: 147-9.

[40] Son CN, Stewart S, Su I, Mihov B, Gamble G, Dalbeth N. Global patterns of treat-to-serum urate target care for gout: Systematic review and meta-analysis. Semin Arthritis Rheum. 2021; 51: 677-84.

[41] Sigurdardottir V, Svärd A, Jacobsson L, Dehlin M. Gout in Dalarna, Sweden - a population-based study of gout occurrence and compliance to treatment guidelines. Scand J Rheumatol. 2023; 52: 498-505.

[42] Russell MD, Roddy E, Rutherford AI, Ellis B, Norton S, Douiri A, et al. Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England. Rheumatology (Oxford). 2023; 62: 2426-34.

[43] Jeyaruban A, Larkins S, Soden M. Management of gout in general practice-a systematic review. Clin Rheumatol. 2015; 34: 9-16.

[44] Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015; 74: 661-7.

[45] Roddy E, Mallen CD, Hider SL, Jordan KP. Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology (Oxford). 2010; 49: 105-11.

[46] Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al.; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012; 64: 1431-46.

[47] Hughes JC, Wallace JL, Bryant CL, Salvig BE, Fourakre TN, Stone WJ. Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout. Ann Pharmacother. 2017; 51: 301-6.

[48] Sautner J, Sautner T. Compliance of Primary Care Providers With Gout Treatment Recommendations- Lessons to Learn: Results of a Nationwide Survey. Front Med (Lausanne). 2020; 7: 244.

[49] Scheepers LEJM, Burden AM, Arts ICW, Spaetgens B, Souverein P, de Vries F, et al. Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). Rheumatology (Oxford). 2018; 57: 1641-50.

[50] Stamp LK, Chapman P, Hudson B, Frampton C, Hamilton G, Judd A. The challenges of managing gout in primary care: Results of a best-practice audit. Aust J Gen Pract. 2019; 48: 631-7.

[51] Gnanenthiran SR, Hassett GM, Gibson KA, McNeil HP. Acute gout management during hospitalization: a need for a protocol. Intern Med J. 2011; 41: 610-7.

[52] Helget LN, O’Dell JR, Newcomb JA, Androsenko M, Brophy MT, Davis-Karim A, et al. Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout. Arthritis Rheumatol. 2024; 76: 638-46.

[53] Singh JA, Yang S, Saag KG. Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort. J Rheumatol. 2020; 47: 449-60.

[54] Rashid N, Coburn BW, Wu YL, Cheetham TC, Curtis JR, Saag KG, et al. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. J Rheumatol. 2015; 42: 504-12.

[55] Koto R, Nakajima A, Horiuchi H, Yamanaka H. Factors associated with achieving target serum uric acid level and occurrence of gouty arthritis: A retrospective observational study of Japanese health insurance claims data. Pharmacoepidemiol Drug Saf. 2021; 30: 157-68.

[56] Singh JA, Hodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis. 2009; 68: 1265-70.

[57] FitzGerald JD, Mikuls TR, Neogi T, Singh JA, Robbins M, Khanna PP, et al. Development of the American College of Rheumatology Electronic Clinical Quality Measures for Gout. Arthritis Care Res (Hoboken). 2018; 70: 659-71.

[58] Al Harash A, Laginya G, Ayoub WT. Efficacy and Outcomes of a Novel Telephone-based Gout Disease Management Program. Open Rheumatol J. 2021; 15: 51-6.

[59] Uhlig T, Karoliussen LF, Sexton J, Borgen T, Haavardsholm EA, Kvien TK, et al. 12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target. RMD Open. 2021; 7: e001628.

[60] Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013; 72: 826-30.

[61] Abhishek A, Jenkins W, La-Crette J, Fernandes G, Doherty M. Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study. Rheumatology (Oxford). 2017; 56: 529-33.

[62] Latif ZP, Nakafero G, Jenkins W, Doherty M, Abhishek A. Implication of nurse intervention on engagement with urate-lowering drugs: A qualitative study of participants in a RCT of nurse led care. Joint Bone Spine. 2019; 86: 357-62.

[63] Ramsubeik K, Ramrattan LA, Kaeley GS, Singh JA. Effectiveness of healthcare educational and behavioral interventions to improve gout outcomes: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis. 2018; 10: 235-52.

[64] Jackson LE, Saag KG, Chiriboga G, Lemon SC, Allison JJ, Mudano A, et al. A multi-step approach to develop a “storytelling” intervention to improve patient gout knowledge and improve outpatient follow-up. Contemp Clin Trials Commun. 2023; 33: 101149.

[65] Krasnoryadtseva A, Dalbeth N, Petrie K. Does seeing personal medical images change beliefs about illness and treatment in people with gout? A randomised controlled trial. Psychol Health. 2020; 35: 107-23.

[66] Emad Y, Dalbeth N, Weinman J, Chalder T, Petrie KJ. Why Do Patients With Gout Not Take Allopurinol? J Rheumatol. 2022; 49: 622-6.